Collaboration - September 22, 2014
Sobi collaborates with Biogen Idec
Sobi is planning to include a new preclinical hemophilia project in an agreement with Biogen Idec. Accodring to an announcement, Sobi has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement […]
Clinical Trials - April 11, 2014
Sobi and Biogen announce positive results from paediatric study
Biogen Idec and Sobi announce positive top-line efficacy and safety results from a phase-3 paediatric study of investigational therapy Eloctate for haemophilia A.